breast cancer
NICE will not back Eisai’s Halaven
November 17, 2011Medical Communications, Sales and Marketing Eisai, Halaven, NICE, breast cancer
NICE has not recommended Eisai’s novel breast cancer drug Halaven due to concerns over its safety and cost.In draft guidance …
FDA’s rejection of Avastin creates conflict
October 31, 2011Research and Development, Sales and Marketing FDA, avastin, breast cancer
Oncology experts have expressed concern at the FDA’s rejection of Roche’s Avastin for the treatment of advanced breast cancer. A …
GSK-Merck back new developing world cancer charity
September 14, 2011Medical Communications Cancer, GSK, Merck & Co, Pink Ribbon-Red Ribbon, breast cancer, cervical cancer
GlaxoSmithKline and Merck are among the backers of a new charity that focuses on preventing female cancers in developing countries. …
NICE blames Faslodex rejection on uncertainties in AZ data
August 23, 2011Sales and Marketing AstraZeneca, Faslodex, NICE, breast cancer
NICE has not recommended a high-dose form of AstraZeneca’s breast cancer drug Faslodex because of uncertainties over its cost-effectiveness. In …
EMA extends Avastin breast cancer licence
July 1, 2011Sales and Marketing avastin, breast cancer, metastatic breast cancer
The EMA has extended the breast cancer licence for Roche’s Avastin after initially restricting the drug’s use. The decision comes …
Eisai launches cancer drug Halaven in UK
April 20, 2011Sales and Marketing Eisai, Halaven, breast cancer
Eisai’s sea sponge derived breast cancer drug Halaven has been launched in the UK following approval from European regulators a …
Eisai marine sponge derived cancer drug approved in Europe
March 23, 2011Sales and Marketing Cancer, Eisai, Halaven, Halichondria okadai, breast cancer, eribulin mesylate
Eisai’s injectible breast cancer drug Halaven has been approved by European regulators. The highly novel drug is made from a …
Eisai prepares ground for Halaven’s European launch
March 7, 2011Sales and Marketing Cancer, EMBRACE, Eisai, Halaven, advanced breast cancer, breast cancer, eribulin
Eisai has published further details of a phase III trial of its first-in-class chemotherapy drug Halaven ahead of its hoped-for …
Avastin’s breast cancer use to continue in Europe
March 2, 2011Sales and Marketing CHMP, Cancer, European Commission, Roche, avastin, bevacizumab, breast cancer, docetaxel, paclitaxel
Roche’s Avastin will remain on the market as a treatment for breast cancer, but only in combination with paclitaxel, the …
NICE yes for Votrient, no to Avastin
February 23, 2011Sales and Marketing Cancer, GSK, GlaxoSmithKline, Kidney cancer, NICE, Roche, avastin, bevacizumab, breast cancer
NICE has recommended GlaxoSmithKline’s kidney cancer drug Votrient on the same day it gave a final negative decision to Roche’s …
Study highlights Avastin heart failure risk
January 6, 2011Research and Development, Sales and Marketing Roche, avastin, bevacizumab, breast cancer
A new study confirms that Roche’s Avastin is linked to a small but significant increased risk of heart failure in …
Roche to challenge FDA on Avastin
December 21, 2010Sales and Marketing EMA, FDA, Roche, avastin, bevacizumab, breast cancer
Roche is set to challenge the decision by the FDA to remove a breast cancer indication from its blockbuster drug …
Novartis pulls Zometa submission after breast cancer failure
December 13, 2010Research and Development, Sales and Marketing Novatis, Zometa, breast cancer, zoledronic
Novartis has pulled Zometa’s marketing application for an early breast cancer indication after the drug failed to meet its primary …
Hormone therapy drugs ‘increase heart disease risk’
December 10, 2010Research and Development AstraZeneca, Hormone therapy, Novartis, Pfizer, aromatase inhibitors, breast cancer, tamoxifen
Three aromatase inhibitors could increase the risk of heart disease in postmenopausal women with breast cancer, according to new data. …
Boehringer puts afatinib head-to-head with Herceptin
December 10, 2010Research and Development BIBW 2992, Boehringer Ingelheim, Herceptin, Roche, Tovok, afatinib, breast cancer
Boehringer Ingelheim has set up a showdown between one of its pipeline oncology products and Roche’s Herceptin. It has started …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
